<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>31 Disorders of coagulation II: Acquired</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-30-disorders-of-coagulation-I-inherited.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 77.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 31 of 40</span>
                    </div>
                    <a href="haematology-32-thrombosis-and-thrombophilia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">31 Disorders of coagulation II: Acquired</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="liver-disease" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                        <span class="heading-text">Liver disease</span>
                    </h2>
                    <div class="content-card">
                        <p>Liver disease leads to defects of coagulation, platelets and fibrinolysis.</p>
                        <ul>
                            <li>Reduced synthesis of vitamin K dependent factors (II, VII, IX, X, proteins C and S) caused by impaired vitamin K absorption (biliary obstruction).</li>
                            <li>Impaired synthesis of other coagulation proteins (factor I and V).</li>
                            <li>Thrombocytopenia (hypersplenism) and abnormal platelet function (cirrhosis).</li>
                            <li>Fibrinolysis impaired.</li>
                            <li>Reduced levels of proteins C and S, antithrombin and $\alpha_{2}$ antiplasmin lead to susceptibility to disseminated intravascular coagulation (DIC).</li>
                            <li>Dysfibrinogenaemia may lead to haemorrhage or thrombosis.</li>
                        </ul>
                    </div>
                </section>

                <section id="dic" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Disseminated intravascular coagulation (Fig. 31.1)</span>
                    </h2>
                    <div class="content-card">
                        <p>Release of procoagulant material into the circulation or endothelial cell damage causes generalized activation of the coagulation and fibrinolytic pathways leading to widespread fibrin deposition in the circulation.</p>
                        
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-087-1.jpg" alt="Fig. 31.1 Flowchart illustrating the causes and effects of disseminated intravascular coagulation (DIC), including underlying conditions like sepsis and trauma, and consequences such as thrombosis, bleeding, and organ failure." class="content-image">
                            <figcaption>Fig. 31.1 Causes and effects of disseminated intravascular coagulation.</figcaption>
                        </figure>

                        <h3 class="subsection-heading">Clinical features</h3>
                        <ul>
                            <li>Both bleeding and thrombosis may occur.</li>
                            <li>Tissue damage caused by thrombosis leads to necrosis and further activation of coagulation and fibrinolysis.</li>
                            <li>Purpura, ecchymoses, gastrointestinal bleeding, bleeding from intravenous sites and following venepuncture may occur as a result of low levels of coagulation factors and platelets resulting from increased consumption.</li>
                            <li>Renal function may be impaired due to microvascular thrombosis.</li>
                            <li>Other manifestations include acute respiratory distress syndrome (both a cause and complication of DIC), adrenal necrosis, shock and thromboembolism.</li>
                        </ul>
                        
                        <h3 class="subsection-heading">Laboratory features (Table 31.1)</h3>
                        <ul>
                            <li>Thrombocytopenia.</li>
                            <li>Nearly all tests of coagulation and fibrinolysis are abnormal with low levels of fibrinogen.</li>
                            <li>Fibrin degradation products (e.g. X-DP or FDP) are present in plasma (X = clotting factor).</li>
                            <li>Blood film: microangiopathic haemolytic anaemia (see Chapter 15) may occur.</li>
                        </ul>

                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Table 31.1 Coagulation changes in acquired disorders of coagulation.</caption>
                                 <thead>
                                     <tr>
                                         <th></th>
                                         <th>PT</th>
                                         <th>APTT</th>
                                         <th>TT</th>
                                         <th>Platelets</th>
                                         <th>Other</th>
                                     </tr>
                                 </thead>
                                 <tbody>
                                     <tr>
                                         <td>Liver disease</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>N/↑</td>
                                         <td>↓</td>
                                         <td>Dysfibrinogenaemia</td>
                                     </tr>
                                     <tr>
                                         <td>DIC</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>↓</td>
                                         <td>FDP ↑ ± RBC fragments on blood film</td>
                                     </tr>
                                     <tr>
                                         <td>Vitamin K deficiency</td>
                                         <td>↑</td>
                                         <td>↑ or N</td>
                                         <td>N</td>
                                         <td>N</td>
                                         <td></td>
                                     </tr>
                                     <tr>
                                         <td>Massive transfusion</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>N</td>
                                         <td>↓</td>
                                         <td></td>
                                     </tr>
                                     <tr>
                                         <td>Oral anticoagulants</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>N</td>
                                         <td>N</td>
                                         <td></td>
                                     </tr>
                                     <tr>
                                         <td>Heparin</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>↑</td>
                                         <td>N (rarely ↓)</td>
                                         <td>Anti-Xa ↓</td>
                                     </tr>
                                 </tbody>
                                 <tfoot>
                                     <tr>
                                        <td colspan="6" style="font-size: 0.9em; padding-top: 1em;">APTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; FDP, fibrin degradation products; N, normal; PT, prothrombin time; RBC, red blood cell; TT, thrombin time.</td>
                                     </tr>
                                 </tfoot>
                             </table>
                        </div>

                        <h3 class="subsection-heading">Treatment</h3>
                        <ul>
                            <li>Treat the cause, e.g. antibiotics, removal of the procoagulant stimulus (e.g. a dead fetus).</li>
                            <li>Supportive therapy with fresh frozen plasma, platelet concentrates and cryoprecipitate if bleeding is dominant.</li>
                            <li>Anticoagulant therapy (e.g. heparin) if thrombosis is dominant.</li>
                            <li>Protein C and antithrombin in selected patients.</li>
                        </ul>
                    </div>
                </section>

                <section id="other-acquired-disorders" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Other acquired disorders of coagulation</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Drugs</h3>
                        <ul>
                            <li>Anticoagulants and drugs affecting anticoagulation (see Chapter 33) are the most common drugs to disturb coagulation.</li>
                            <li>Chemotherapy (e.g. l-asparaginase may lead to thrombosis).</li>
                        </ul>

                        <h3 class="subsection-heading">Acquired coagulation inhibitors</h3>
                        <p>These antibodies to coagulation factors are idiopathic, commoner in the elderly, or occur in malignancy (e.g. lymphoma), connective tissue disease (e.g. SLE) and with paraproteins (e.g. myeloma). They lead to excessive bleeding, both spontaneously and following injury.</p>
                        
                        <h3 class="subsection-heading">Vitamin K deficiency</h3>
                        <p>Vitamin K is required to activate factors II, VII, IX and X and protein C and S by $\gamma$ carboxylation (see Chapter 33). It is fat-soluble and derived from vegetables in food and intestinal flora. Deficiency occurs in patients on poor diets, those taking broad-spectrum antibiotics which reduce the gut flora, in biliary tract disease and with intestinal malabsorption.</p>
                        
                        <h3 class="subsection-heading">Haemorrhagic disease of the newborn</h3>
                        <p>Newborn infants are at an increased risk of bleeding because of hepatic immaturity and low levels of vitamin K. It is customary to give an injection of vitamin K (1 mg) to all newborn infants in the UK. Fears that this may lead to an increased risk of cancer have not been substantiated.</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-30-disorders-of-coagulation-I-inherited.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 77.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 31 of 40</span>
                    </div>
                    <a href="haematology-32-thrombosis-and-thrombophilia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>